A Retrospective Analysis of Safety and Efficacy of Everolimus in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients That Showed Progression after PRRT Abstract #712

Introduction: GEP-NET patients have been treated successfully with SSAs. Upon progression, peptide receptor radiotherapy (PRRT) with 177Lu-octreotate is successful. PRRT is not unlimited. Some patients became refractory after therapy. There is a high medical need. Everolimus (mTOR inhibitor) is a promising therapy for progressive G1/G2 GEP-NETs, with well-established safety. Everolimus has shown efficacy in patients with (non-)PNET (RADIANT-2/-3). However, toxicity data of Everolimus after PRRT is lacking.
Aim(s): Investigate whether the safety profile of Everolimus is different after failure of PRRT.
Materials and methods: Seven men and six women (median age: 54.5 years) that received Everolimus (5 or 10 mg) at least once directly after PRRT failure were included. Baseline: last documented characteristics prior initiation Everolimus. Patients were assessed for safety parameters at baseline, including previously reported adverse events during PRRT and laboratory values. Progression-free survival (PFS) was analyzed using a KM curve.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: drs. Kimberly Kamp

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result